Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-608 in moderate-to-severe plaque psoriasis
NCT06299982Phase 3Not yet recruiting
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- May 2024
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of 608 in plaque psoriasis, sponsored by 3S Guojian Pharmaceutical. Planned start May 2024; status: not yet recruiting.
02
Drugs
608
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06299982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06299982.